Kliniken Essen-Mitte, Klinik für Senologie/ Interdisziplinäres Brustzentrum

Essen 45136

0 studies enrolling now · 2 studies all time

What they study most

Fatigue, HER2-Positive Primary Breast Cancer, Locally Advanced or Metastatic Breast Cancer, Residual Invasive Breast Cancer

Studies at this site

• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer — Withdrawn before enrolling